Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c) is a 16-amino acid peptide with one of the most distinctive provenances in modern biology: it is encoded within the mitochondrial genome itself rather than nuclear DNA, making it the founding member of the recognized class of mitochondrial-derived peptides (MDPs) and the first MDP in this library. The compound was formally characterized in 2015 by Pinchas Cohen's laboratory at the USC Leonard Davis School of Gerontology (Lee et al., Cell Metabolism), fundamentally expanding our understanding of mitochondria from passive 'energy factories' to active endocrine organs that produce signaling peptides influencing whole-body metabolism.
This is paradigm-shifting biology. Until the MOTS-c discovery, the mitochondrial genome was viewed primarily as encoding the 13 core proteins of the electron transport chain plus the rRNAs and tRNAs needed for mitochondrial translation. The recognition that small open reading frames within mitochondrial rRNA regions encode bioactive peptides, and that those peptides can be secreted into circulation, act on distal tissues, and even translocate back into the nucleus to regulate gene expression (Kim et al. 2018, Cell Metabolism), recast our model of mitochondrial biology. Mitochondria are no longer just power plants. They are signaling hubs that communicate with the rest of the cell, and with other cells through circulating MDPs.
MOTS-c sits at the intersection of mitochondrial biology, metabolic regulation, and exercise physiology. The peptide is induced by acute exercise (11.9-fold increase in skeletal muscle in Lee et al. 2016), engages AMPK (the master cellular energy sensor) and downstream metabolic pathways, improves insulin sensitivity and glucose handling in animal models, and demonstrates cardioprotective effects across multiple studies. This has supported the 'exercise mimetic' framing: the idea that MOTS-c engages exercise-related cellular pathways and produces effects resembling trained metabolic states.
This framing is real but imprecise. MOTS-c does engage exercise-related cellular pathways. MOTS-c is induced by exercise. But 'mimics exercise' is not the same as 'replaces exercise'. The evidence does not support full equivalence. Users encountering MOTS-c through non-medical channels should not substitute it for actual physical activity. The exercise-mimetic framing is most useful as a mechanistic descriptor (similar AMPK engagement), least useful as a substitution rationale.
MOTS-c development has stagnated despite the scientific interest. CohBar Inc. (founded by Cohen's lab to commercialize MDP-based therapeutics) pursued a Phase 1 clinical trial for hepatic steatosis but has had financial difficulties; clinical development has not advanced to Phase 2/3. The stagnation reflects pharmaceutical economic challenges for endogenous-sequence peptides (limited patent protection, delivery challenges, slow human translation) more than safety signals. As a result, MOTS-c sits in an unusual position: paradigm-shifting basic biology, encouraging animal pharmacology, exercise-induction empirical basis, and stagnated clinical development with no approved indication.
Related MDPs include humanin (24 aa, encoded in the 16S rRNA region, a separate ORF from MOTS-c's 12S region), SHLPs (small humanin-like peptides) 1–6, and other mitochondrial ORFs being characterized. The MDP class is expanding as researchers re-examine mitochondrial rRNA regions for additional bioactive ORFs.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous MOTS-c | Short (minutes range for parent peptide) |
| Intramuscular MOTS-c | Variable |
| Intravenous MOTS-c | Variable |
| Oral MOTS-c | Not feasible |
What it does
Main effects
- First mitochondrial-derived peptide (MDP) in the library, paradigm-shifting biology: Encoded by the mitochondrial 12S rRNA region (mtDNA, not nuclear DNA); demonstrates mitochondria are active endocrine organs producing signaling peptides; recasts our model of mitochondrial-nuclear communication
- AMPK pathway activation: Major cellular energy sensor; downstream effects on glucose handling, fatty acid oxidation, mitochondrial biogenesis, metabolic flexibility; the mechanistic basis for 'exercise mimetic' framing
- Nuclear translocation under metabolic stress (Kim et al. 2018, Cell Metabolism): MOTS-c translocates from cytoplasm to nucleus under glucose restriction and other stress signals, directly regulating nuclear gene expression. Remarkable mitochondrial-to-nuclear retrograde signaling
- Insulin sensitivity enhancement: Multiple animal studies; mechanism via AMPK and other pathways; plasma MOTS-c decreased in type 2 diabetes subjects (Ramanjaneya et al.)
- Exercise induction (11.9-fold): Acute exercise increases skeletal muscle MOTS-c expression dramatically (Lee et al. 2016), the empirical basis for 'exercise mimetic' framing
- Cardioprotective effects: Multiple studies demonstrate reduced oxidative stress, improved glycolipid metabolism, increased glucose utilization, improved endothelial function in cardiovascular tissues
- Beta-oxidation increase: Improved fatty acid metabolism documented
- Plasma MOTS-c decreases with aging: Supplementation hypothesized to compensate for age-related decline; mechanistic alignment with longevity research
- Founding member of MDP class: Related peptides include humanin (24 aa, 16S rRNA), SHLPs 1–6, and other mitochondrial ORFs being characterized; the MDP class is expanding
What to watch for
Common side effects
- 'Exercise mimetic' framing is real but imprecise: MOTS-c does engage exercise-related cellular pathways (AMPK, mitochondrial biogenesis) and is induced by exercise, but 'mimics exercise' is NOT the same as 'replaces exercise'. Evidence does not support full equivalence; users should not substitute MOTS-c for actual physical activity
- Very limited human clinical data: Phase 1 hepatic steatosis trial (CohBar) was conducted but has not advanced to Phase 2/3; CohBar Inc. has had financial difficulties; clinical development has stagnated
- CohBar Inc. commercialization difficulties: Pinchas Cohen's lab founded CohBar to commercialize MDP-based therapeutics; financial difficulties have stagnated translation to approved therapy; stagnation is NOT primarily a safety signal but reflects pharmaceutical economic challenges for endogenous-sequence peptides
- Delivery and stability challenges: Low bioavailability, poor stability, short half-life all limit therapeutic translation; subcutaneous delivery is most common in research and non-medical use
- Patent and economic challenges: Limited patent protection for endogenous mitochondrial sequences has discouraged sustained pharmaceutical investment
- Translation gap from animal findings: Animal model results have been encouraging but human translation has been slow; users should not assume human equivalence
- Research chemical quality concerns: No pharmaceutical-grade source exists; identity, concentration, sterility unverified across the supply chain
- No long-term safety data in humans: Even acute safety in Phase 1 is limited; chronic-use safety unknown
- Mild injection-site reactions: Standard for SC peptide administration
- WADA status uncertain: Markdown source states 'not specifically prohibited as of current information'; other sources suggest MOTS-c may have been added to the Prohibited List under exercise-mimetic categories in 2024; status may continue to evolve; users in tested sport should verify current WADA Prohibited List directly before any use
- Hypothetical concern about systemic AMPK activation: Sustained AMPK pathway engagement has been hypothesized to affect cellular processes beyond metabolism; long-term consequences in humans are not characterized
Key facts
Key facts worth knowing
- MOTS-c is a 16-amino acid peptide encoded by the 12S rRNA region of the mitochondrial genome (mtDNA, not nuclear DNA). Sequence: MRWQEMGYIFYPRKLR. Molecular weight 2174.59 Da. The mitochondrial DNA origin is the single most distinctive feature of MOTS-c and the foundational fact about the compound.
- First mitochondrial-derived peptide (MDP) in this library: paradigm-shifting biology. Until the MOTS-c discovery, mitochondrial DNA was viewed primarily as encoding the 13 ETC proteins plus rRNAs/tRNAs. The recognition that small ORFs within mitochondrial rRNA regions encode bioactive peptides that can be secreted, act on distal tissues, and translocate to the nucleus recast our model of mitochondrial biology. Mitochondria are not just power plants. They are signaling hubs.
- Formally characterized 2015 by Pinchas Cohen's lab at USC Leonard Davis School of Gerontology in a landmark Cell Metabolism paper (Lee et al. 2015). Cohen is Dean of USC Leonard Davis School of Gerontology and the central figure in MDP research. Subsequent work has expanded characterization across multiple groups. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443-454.
- Nuclear translocation discovery (Kim et al. 2018, Cell Metabolism). Demonstrated that MOTS-c translocates from cytoplasm to nucleus under glucose restriction and other metabolic stress signals, directly regulating nuclear gene expression. This is mitochondrial-to-nuclear retrograde signaling: a mitochondrially-encoded peptide entering the nucleus to control nuclear gene transcription. Remarkable biology that further established the MDP signaling paradigm. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism 2018;28(3):516-524.
- Exercise induction (Lee et al. 2016). Acute exercise induces an 11.9-fold increase in MOTS-c expression in skeletal muscle. This is the empirical basis for the 'exercise mimetic' framing. The induction is dramatic, among the largest exercise-induced changes observed for any peptide. MOTS-c thus appears to be an exercise-responsive signaling peptide originating from mitochondria, plausibly mediating some adaptive metabolic responses to physical activity.
- 'Exercise mimetic' framing is real but imprecise. MOTS-c engages exercise-related cellular pathways (AMPK, mitochondrial biogenesis); MOTS-c is induced by exercise (11.9-fold); MOTS-c improves exercise capacity in obese mice; MOTS-c rejuvenates aging phenotypes in mouse muscle. So the framing has empirical basis. BUT 'mimics exercise' does not equal 'replaces exercise'. Evidence does not support full equivalence. Users encountering MOTS-c through non-medical channels should not substitute it for actual physical activity. The framing is most useful as a mechanistic descriptor, least useful as a substitution rationale.
- MDP class · related compounds: Humanin (24 aa, encoded in the 16S rRNA region, a separate ORF from MOTS-c's 12S region; older discovery; substantial separate literature on cytoprotection and neuroprotection). SHLPs 1–6 (small humanin-like peptides, additional ORFs in the 16S rRNA region). Other mitochondrial ORFs are being characterized as the MDP class expands. MOTS-c is the founding 'metabolic' MDP; humanin is the founding 'cytoprotective' MDP.
- Pinchas Cohen and CohBar Inc. Cohen's lab discovered MOTS-c and founded CohBar Inc. to commercialize MDP-based therapeutics. CohBar pursued a Phase 1 hepatic steatosis trial with a MOTS-c analog but has had financial difficulties; clinical development has stagnated. The stagnation is NOT primarily a safety signal. It reflects pharmaceutical economic challenges for endogenous-sequence peptides (limited patent protection, delivery challenges, slow human translation).
- Plasma MOTS-c characteristics: Levels are similar overall between lean and obese individuals; correlations with insulin resistance indices differ; decreased in type 2 diabetes subjects (Ramanjaneya et al.); decreases with aging generally; increased with acute exercise dramatically. The decrease with aging is the alignment point with longevity research. Supplementation is hypothesized to compensate for age-related MDP decline.
- Cardioprotective effects documented in multiple studies: reduced oxidative stress in cardiovascular tissues; improved glycolipid metabolism; increased glucose utilization; improved endothelial function; some protection in cardiac stress models. Cardiovascular MOTS-c biology is a distinct emerging area of research.
Legal status
Legal status
No FDA approval. Phase 1 clinical trial conducted for hepatic steatosis (CohBar Inc.) but has not advanced to Phase 2/3. WADA status uncertain: sources differ; users in tested sport should verify current WADA Prohibited List directly. Not on FDA bulk drug substance lists for compounding.